| Hazard ratio | P value | 95% CI |
---|---|---|---|
Demographics | |||
 Age (years) | 1.058 | 0.002 | 1.021–1.095 |
 Gender, male | 1.073 | 0.870 | 0.464–2.480 |
Laboratory data | |||
 CRP (mg/dl) | 1.321 | <0.0001 | 1.140–1.531 |
 Serum albumin (g/dl) | 0.414 | 0.051 | 0.171–1.004 |
 Serum creatinine (mg/dl) | 1.358 | 0.413 | 0.652–2.828 |
RA characteristics | |||
 RA duration (years) | 1.002 | 0.927 | 0.968–1.036 |
 HAQ | 1.219 | 0.366 | 0.794–1.871 |
 DAS28 (CRP) | 0.894 | 0.498 | 0.646–1.237 |
 SDAI | 0.970 | 0.281 | 0.919–1.025 |
 CDAI | 0.949 | 0.115 | 0.890–1.013 |
Comorbidity | |||
 Smoking history | 0.936 | 0.877 | 0.405–2.165 |
 Cardiovascular disease | 1.745 | 0.122 | 0.862–3.533 |
 Metabolic disease | 1.612 | 0.211 | 0.763–3.405 |
 CKD | 1.814 | 0.415 | 0.433–7.592 |
 Autoimmune disease | 0.723 | 0.750 | 0.099–5.299 |
 Interstitial pneumonia | 4.449 | <0.0001 | 2.143–9.237 |
PPSV23 vaccination | 1.048 | 0.894 | 0.523–2.099 |
Treatment | |||
 PSL | 1.314 | 0.443 | 0.654–2.643 |
 Dose of prednisolone (mg/day) | 1.117 | 0.102 | 0.978–1.276 |
 MTX | 0.778 | 0.493 | 0.381–1.593 |
 Dose of MTX (mg/week) | 0.962 | 0.634 | 0.821–1.128 |
 TAC | 0.956 | 0.934 | 0.335–2.727 |
 Biologics | 0.544 | 0.088 | 0.270–1.094 |